Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Caterpillar Inc (CAT) vs Novavax Inc (NVAX) Price & Performance

Caterpillar IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Caterpillar Inc vs Novavax Inc — how do they compare? Caterpillar Inc trades at $849.29 (market cap $385.01B), while Novavax Inc trades at $7.96 (market cap $1.30B). The key difference: Caterpillar Inc is far larger — about 296.2× Novavax Inc's market cap, and Caterpillar Inc pays a 0.78% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

CATNVAX
Market Cap
$385.01B$1.30B
Sector
IndustrialsHealth
52-Week High
$1.06K$11.19
52-Week Low
$407.79$6.22
Enterprise Value
$423.45B$879.40M
Dividend Yield
0.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Caterpillar Inc

Caterpillar (CAT) trades at $843.37, up 0.14% on the day, with strong year-to-date performance driven by robust earnings beats and AI data center demand. The stock shows a bearish technical signal but maintains solid fundamentals, including a net income margin of 14.51% and ROE of 56.99%. Recent news highlights growth from power and energy segments, with a dividend increase expected in June 2026.

Outlook remains positive due to earnings momentum and infrastructure tailwinds, though elevated valuation ratios like a P/E of 36.07 pose risks. Analyst consensus is bullish with a $1,010 price target, but investors should monitor economic cycles and competitive pressures that could impact future performance.

Novavax Inc

Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.

Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Caterpillar Inc

Caterpillar Inc. designs, manufactures, and markets construction, mining, and forestry machinery. The Company also manufactures engines and other related parts for its equipment, and offers financing and insurance. Caterpillar distributes its products through a worldwide organization of dealers.

Read more on CAT

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX